GeoVax Labs, Inc. (GOVX)

Market Cap	13.51M
Revenue (ttm)	n/a
Net Income (ttm)	-19.32M
Shares Out	26.44M
EPS (ttm)	-0.74
PE Ratio	n/a
Forward PE	10.63
Dividend	n/a
Ex-Dividend Date	n/a

Volume	119,375
Open	0.516
Previous Close	0.511
Day's Range	0.510 - 0.534
52-Week Range	0.505 - 1.390
Beta	2.94
Analysts	Strong Buy
Price Target	6.00 (+1,074.63%)
Earnings Date	Nov 8, 2023

About GOVX

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM0...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 14
• Stock Exchange: NASDAQ
• Ticker Symbol: GOVX

Financial Performance

In 2022, GeoVax Labs's revenue was $81,526, a decrease of -78.85% compared to the previous year's $385,501. Losses were -$14.02 million, -24.50% less than in 2021.

Analyst Forecast

According to 3 analysts, the average rating for GOVX stock is "Strong Buy." The 12-month stock price forecast is $6.0, which is an increase of 1,074.63% from the latest price.

Price Target

$6.0

(1,074.63% upside)

Analyst Consensus: Strong Buy